Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation

Galecto Appoints New Chair and Strengthens Board of Directors

Galecto Appoints Jonathan Freve as Chief Financial Officer

AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

AM-Pharma B.V., today announces that it has raised additional funds of €47m [US$52m], increasing the total recent fundraising to €163m [US$176m].

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

Light-Activated AU-011 Holds Significant Potential as a First Line Treatment for Choroidal Melanoma.

Xeltis trials show promising function of living heart valves restored in children

Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves developed in patients as a result of its restorative implants.

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis

Sanifit, today announced that the first patient has successfully been dosed in its pivotal phase 3 trial of the Company’s lead asset SNF472.

CorWave Appoints Jim Schuermann as an Independent Director

CorWave, announced today the election of Jim Schuermann to its board of directors.

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Galecto, Inc., today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics, today announces that its lead drug candidate leriglitazone (MIN-102) has been granted fast track designation by the US Food and Drug Administration.